Dr. Robert B. Stein Named President of Roche Palo Alto
PALO ALTO, Calif., August 28, 2003 – Roche today announced the appointment of Robert B. Stein, M.D., Ph.D., as president of Roche Palo Alto, effective September 22. Dr. Stein succeeds James N. Woody, M.D., Ph.D., who is leaving the company after seven years in his current position.
Dr. Stein joins Roche from Incyte Corporation where he was president and chief scientific officer. Dr. Stein has spent more than 20 years in the pharmaceutical and biotechnology industries at companies including Merck, Ligand and Merck DuPont and DuPont Pharmaceuticals, in addition to Incyte. He has participated in the discovery and development of six marketed medicines.
After receiving undergraduate degrees in biology and chemistry from Indiana University, Dr. Stein studied at Duke University where he received a Ph.D. in physiology and pharmacology and an M.D. He completed residency training and is board certified in anatomic and clinical pathology.
He joined the pharmaceutical industry in 1982 at Merck Laboratories. In his new position, Dr. Stein will report to Jonathan Knowles, head of Global Research for Roche.
“Dr. Stein brings to Roche tremendous knowledge in diverse areas of drug discovery,” said Knowles. “He has extensive experience in disease areas including virology, inflammation and central nervous system disorders. He has worked with leading edge technologies and has headed both large and small research organizations. Building on the legacy of Jim Woody, I expect that Dr. Stein will contribute extensively to our drug discovery endeavors, both in his role as the leader of Palo Alto research and as a member of our global research management organization.”
Dr. Stein serves on the University of California President’s Advisory Board for Science and Innovation.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche employs approximately 65,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.
Roche Palo Alto is focused on the discovery and early clinical development of new medicines to treat arthritis; respiratory diseases including asthma and emphysema; central nervous system disorders including Alzheimer's disease, anxiety, depression and schizophrenia; incontinence and other genitourinary disorders; and viral diseases including HIV/AIDS and hepatitis C. Roche employs approximately 1,000 people at its 70-acre Palo Alto campus.
Following are URLs for Roche on the web:
Global website: www.roche.com.
U.S. pharmaceuticals business: www.rocheusa.com
Roche Palo Alto: http://paloalto.roche.com
